Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosis
Abstract
Atherosclerosis is a disease of chronic inflammation. We investigated the roles of the cytokines IL-4 and IL-13, the classical activators of STAT6, in the resolution of atherosclerosis inflammation. Using Il4-/-Il13-/- mice, resolution was impaired, and in control mice, in both progressing and resolving plaques, levels of IL-4 were stably low, and IL-13 was undetectable. This suggested that IL-4 is required for atherosclerosis resolution, but collaborates with other factors. We had observed increased Wnt signaling in macrophages in resolving plaques, and human genetic data from others showed that a loss-of-function Wnt mutation was associated with premature atherosclerosis. We now find an inverse association between activation of Wnt signaling and disease severity in mice and humans. Wnt enhanced the expression of inflammation resolving factors after treatment with plaque-relevant low concentrations of IL-4. Mechanistically, activation of the Wnt pathway following lipid lowering potentiates IL-4 responsiveness in macrophages via a PGE2/STAT3 axis.
Data availability
The RNA sequencing data will be deposited in GEO under accession number GSE168542.
-
Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosisNCBI Gene Expression Omnibus, GSE168542.
Article and author information
Author details
Funding
National Heart, Lung, and Blood Institute (K23HL135398)
- Sean P Heffron
National Heart, Lung, and Blood Institute (K99HL151963)
- Ada Weinstock
American Heart Association (20SFRN35210252)
- Chiara Giannarelli
National Heart, Lung, and Blood Institute (R03HL13528)
- Chiara Giannarelli
National Heart, Lung, and Blood Institute (K23HL111339)
- Chiara Giannarelli
National Heart, Lung, and Blood Institute (R21TR001739)
- Chiara Giannarelli
National Heart, Lung, and Blood Institute (UH2/3TR002067)
- Chiara Giannarelli
National Heart, Lung, and Blood Institute (5T23HL007824)
- Dawn Fernandez
National Heart, Lung, and Blood Institute (HL106173)
- Matthew Spite
National Heart, Lung, and Blood Institute (GM095467)
- Matthew Spite
National Heart, Lung, and Blood Institute (HL084312)
- Edward A Fisher
National Heart, Lung, and Blood Institute (HL136044)
- Brian E Sansbury
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (AI130945)
- P'ng Loke
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (AI133977)
- P'ng Loke
National Heart, Lung, and Blood Institute (HL084312)
- P'ng Loke
U.S. Department of Defense (W81XWH-16-1-0256)
- P'ng Loke
American Heart Association (18POST34080390)
- Ada Weinstock
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (T32AI100853)
- Karishma Rahman
National Heart, Lung, and Blood Institute (F30HL131183)
- Karishma Rahman
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the protocol (number IA16-00494) approved by the Institutional Animal Care and Use Committee of the New York University School of Medicine.
Reviewing Editor
- Jameel Iqbal, James J. Peters Veterans Affairs Medical Center, United States
Publication history
- Received: February 27, 2021
- Accepted: March 1, 2021
- Accepted Manuscript published: March 15, 2021 (version 1)
- Accepted Manuscript updated: March 17, 2021 (version 2)
- Version of Record published: March 25, 2021 (version 3)
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 2,493
- Page views
-
- 325
- Downloads
-
- 7
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Immunology and Inflammation
The tongue is a unique muscular organ situated in the oral cavity where it is involved in taste sensation, mastication, and articulation. As a barrier organ, which is constantly exposed to environmental pathogens, the tongue is expected to host an immune cell network ensuring local immune defence. However, the composition and the transcriptional landscape of the tongue immune system are currently not completely defined. Here, we characterised the tissue-resident immune compartment of the murine tongue during development, health and disease, combining single-cell RNA-sequencing with in situ immunophenotyping. We identified distinct local immune cell populations and described two specific subsets of tongue-resident macrophages occupying discrete anatomical niches. Cx3cr1+ macrophages were located specifically in the highly innervated lamina propria beneath the tongue epidermis and at times in close proximity to fungiform papillae. Folr2+ macrophages were detected in deeper muscular tissue. In silico analysis indicated that the two macrophage subsets originate from a common proliferative precursor during early postnatal development and responded differently to systemic LPS in vivo. Our description of the under-investigated tongue immune system sets a starting point to facilitate research on tongue immune-physiology and pathology including cancer and taste disorders.
-
- Immunology and Inflammation
B cells contribute to the pathogenesis of polycystic ovary syndrome (PCOS). Clinically, metformin is used to treat PCOS, but it is unclear whether metformin exerts its therapeutic effect by regulating B cells. Here, we showed that the expression level of TNF-α in peripheral blood B cells from PCOS patient was increased. Metformin used in vitro and in vivo was able to reduce the production of TNF-α in B cells from PCOS patient. Administration of metformin improved mouse PCOS phenotypes induced by dehydroepiandrosterone (DHEA) and also inhibited TNF-α expression in splenic B cells. Further, metformin induced metabolic reprogramming of B cells in PCOS patients, including the alteration in mitochondrial morphology, the decrease in mitochondrial membrane potential, ROS production and glucose uptake. In DHEA-induced mouse PCOS model, metformin altered metabolic intermediates in splenic B cells. Moreover, the inhibition of TNF-α expression and metabolic reprogramming in B cells of PCOS patients and mouse model by metformin were associated with decreased mTOR phosphorylation. Together, TNF-α-producing B cells are involved in the pathogenesis of PCOS, and metformin inhibits mTOR phosphorylation and affects metabolic reprogramming, thereby inhibiting TNF-α expression in B cells, which may be a new mechanism of metformin in the treatment of PCOS.